Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : DYAX: Dyax Corp. -- Ignore unavailable to you. Want to Upgrade?

To: mcbio who wrote (162)	3/5/2008 9:01:37 AM
From: idos	Read Replies (1) \| Respond to of 197

> what you think the results will be? < DX-88 is a good drug. EDEMA-3 has achieved all of its primary and secondary endpoints. EDEMA-4 is an SPA-sponsored trial. I think results are very likely to be positive. > If positive, do you think we'll get a nice bump< When they will releases the Phase III results and advances towards BLA filing I do think the stock will gain. Still, I don't think we'll see a huge bump. The market is small and going to be crowded: LEVP were delayed but can still get FDA approval in mid-08 (and receive orphan exclusivity). Jerini could also ultimately reach the market. There are also competitors developing C1 esterase inhibitors (C1-INHs). Plus DYAX intend to market in the US on their own and they still don't have a partner for ex US.